HIV, Buprenorphine, and the Criminal Justice System

Completed · Not applicable · Has a placebo group

Conditions studied: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence

In brief

The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.

Key facts

Study ID

NCT01550341

Run by

Yale University

People needed

50

Starts

2012-02-23

Expected to finish

2016-11-30

Last updated by the study team

2020-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV+
• Age ≥18 yrs
• Meets DSM-IV criteria for opioid dependence
• Has medical entitlements in DC
• Able to provide informed consent
• Able to communicate in English or Spanish

You may not qualify if…

• Being prescribed an opiate medication for a chronic pain condition or expressing the need to be placed on chronic pain medical conditions for a documented pain condition
• Currently receiving methadone dosing of over 30 mg per day and uninterested in changing to buprenorphine
• AST and ALT >5x the upper limit of normal (AST≥175, ALT≥195)
• Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera, condoms, etc.)
• Breastfeeding or unwilling to stop breastfeeding
• Subject is part of another pharmacological research study
• Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)
• Suicidal ideation
• Hypersensitivity to buprenorphine

Where it is running

• Howard University — Washington D.C., District of Columbia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.